citric acid, anhydrous has been researched along with Acidemia Propionic in 3 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propionic acidemia (PA) and methylmalonic acidemia (MMA) are autosomal recessive disorders of propionyl-CoA (P-CoA) catabolism, which are caused by a deficiency in the enzyme propionyl-CoA carboxylase or the enzyme methylmalonyl-CoA (MM-CoA) mutase, respectively." | 7.96 | Biochemical and anaplerotic applications of in vitro models of propionic acidemia and methylmalonic acidemia using patient-derived primary hepatocytes. ( Armstrong, AJ; Chapman, KA; Collado, MS; Day, N; Figler, RA; Hoang, SA; Olson, M; Reardon, J; Summar, M; Wamhoff, BR, 2020) |
| "5mEq/kg per day), or ornithine α-ketoglutarate (400mg/kg per day) (anaplerotic agents that could fill up the citric acid cycle) would affect plasma levels of glutamine and ammonia, the urinary excretion of Krebs cycle intermediates, and the clinical outcome in 3 patients with propionic acidemia." | 5.24 | Anaplerotic therapy in propionic acidemia. ( Bailey, C; Cantor, NL; Ernst, SL; Gappmaier, E; Longo, N; Pasquali, M; Price, LB, 2017) |
| "Propionic acidemia (PA) and methylmalonic acidemia (MMA) are autosomal recessive disorders of propionyl-CoA (P-CoA) catabolism, which are caused by a deficiency in the enzyme propionyl-CoA carboxylase or the enzyme methylmalonyl-CoA (MM-CoA) mutase, respectively." | 3.96 | Biochemical and anaplerotic applications of in vitro models of propionic acidemia and methylmalonic acidemia using patient-derived primary hepatocytes. ( Armstrong, AJ; Chapman, KA; Collado, MS; Day, N; Figler, RA; Hoang, SA; Olson, M; Reardon, J; Summar, M; Wamhoff, BR, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Collado, MS | 1 |
| Armstrong, AJ | 1 |
| Olson, M | 1 |
| Hoang, SA | 1 |
| Day, N | 1 |
| Summar, M | 1 |
| Chapman, KA | 1 |
| Reardon, J | 1 |
| Figler, RA | 1 |
| Wamhoff, BR | 1 |
| Longo, N | 1 |
| Price, LB | 1 |
| Gappmaier, E | 1 |
| Cantor, NL | 1 |
| Ernst, SL | 1 |
| Bailey, C | 1 |
| Pasquali, M | 1 |
| Siekmeyer, M | 1 |
| Petzold-Quinque, S | 1 |
| Terpe, F | 1 |
| Beblo, S | 1 |
| Gebhardt, R | 1 |
| Schlensog-Schuster, F | 1 |
| Kiess, W | 1 |
| Siekmeyer, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety & Efficacy of Investigational Products: Ornithine Alpha-ketoglutarate, Glutamine, or Disodium Citrate on Hyperammonemia in Propionic Acidemia.[NCT00645879] | Phase 1 | 3 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for citric acid, anhydrous and Acidemia Propionic
| Article | Year |
|---|---|
Anaplerotic therapy in propionic acidemia.
Topics: Amino Acids; Ammonia; Carbon-Carbon Ligases; Child; Child, Preschool; Citrates; Citric Acid; Citric | 2017 |
2 other studies available for citric acid, anhydrous and Acidemia Propionic
| Article | Year |
|---|---|
Biochemical and anaplerotic applications of in vitro models of propionic acidemia and methylmalonic acidemia using patient-derived primary hepatocytes.
Topics: Amino Acid Metabolism, Inborn Errors; Amino Acids; Case-Control Studies; Cells, Cultured; Citrates; | 2020 |
Citric acid as the last therapeutic approach in an acute life-threatening metabolic decompensation of propionic acidaemia.
Topics: Acute Disease; Anticoagulants; Child; Citric Acid; Citric Acid Cycle; Critical Illness; Energy Metab | 2013 |